Risultati della ricerca - Dingkuan Xu

Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study di Xiaoqing Yan, Ming Ye, Qing Zou, Peng Chen, Z.S. He, Bin Wu, Dalin He, Chao‐Hong He, Xue‐Yi Xue, Zhengguo Ji, Hui Chen, Xiaofeng Zhang, Yanshi Liu, Xiaodong Zhang, Cheng Fu, Dingkuan Xu, Qiu Ming-xing, J. Lv, Jian Huang, Xiaosong Ren, Ying Cheng, Weijun Qin, Xiaofang Zhang, Fangjian Zhou, Linlin Ma, Jianming Guo, De‐Gang Ding, Shuang Wei, Yi He, Hongqian Guo, Benkang Shi, Li Liu, Feng Liu, Zhiquan Hu, Xiaoping Jin, Li Yang, Shenghui Zhu, Jihong Liu, Yuehua Huang, Tao Xu, Ben Liu, Ting Sun, Zi-Wen Wang, H.W. Jiang, Dan Yu, Aiping Zhou, Jun Jiang, Guohui Luan, Chunlan Jin, Jianming Xu, Juntao Hu, Yanyou Huang, Jun Guo, Wei Zhai, Xinan Sheng